|

Ruxolitinib (JAKAVI®) Clinical Trials

2 actively recruiting trials across 1 location

▲ +1 trial since May 2026

Pipeline

Phase 1: 1Phase 2/3: 1

Top Sponsors

  • Stephan Grupp MD PhD1
  • Federal Research Institute of Pediatric Hematology, Oncology and Immunology1

Indications

  • Cancer2
  • Acute Lymphoblastic Leukemia, Relapse1
  • Acute Myeloid Leukemia, High Risk1
  • Acute Lymphoblastic Leukemia, High Risk1
  • Acute Myeloid Leukemia, Relapsed1

Other1 trial

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Phase 2/3

Philadelphia, Pennsylvania1 trial

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

Children's Hospital of Philadelphia

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.